Xaliproden
Alternative Names: SR 57746; SR 57746A; Xaliproden hydrochloride; xaliprodene; XaprilaLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Class Naphthalenes; Neuroprotectants; Nootropics; Pyridines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer pain; Multiple sclerosis
Most Recent Events
- 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Australia (PO)
- 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Canada (PO)
- 29 Jul 2009 Discontinued - Phase-III for Cancer pain in Europe (PO)